The Society for Neuro-Oncology (SNO) marks its 30th anniversary in 2025, providing an opportunity to reflect on scientific advances and future directions on the field. Over three decades, SNO has catalyzed scientific innovation, education, mentorship, and global collaboration, advancing the care of patients with primary and metastatic brain tumors. Through its annual meeting and subspecialty conferences in pediatric neuro-oncology and brain metastases, as well as its journals, including Neuro-Oncology, Neuro-Oncology Practice, Neuro-Oncology Advances, and the recently launched Neuro-Oncology Pediatrics, SNO has established leading platforms for disseminating knowledge, sharing best practices, and shaping clinical, translational, and basic research worldwide. Scientific milestones during this period include the integration of molecular profiling into CNS tumor classification, advances in neuroimaging for diagnosis and treatment monitoring, targeted therapies for selected glioma patients and the evolution of brain metastases management from whole-brain radiotherapy to multimodal strategies that incorporate targeted and immune-based therapies. Pediatric neuro-oncology has similarly advanced with the use of histomolecular diagnostics, refined risk stratification, and the development of novel targeted agents, alongside an increased emphasis on survivorship. Looking forward, emerging insights into the tumor microenvironment and novel immunotherapeutic approaches offer promising directions for future discovery and translation.
- Reflecting on Scientific Growth and Innovation as the Society for Neuro-Oncology Turns 30
- Macarena I De La Fuente - University of MiamiPriscilla K Brastianos - Harvard UniversityBradley Gampel - University of MiamiFarshad Nassiri - University of TorontoDavid R Raleigh - University of California, San FranciscoCristiane M Ida - Mayo Clinic in ArizonaMohamed S Abdelbaki - St. Louis Children's HospitalMelike Pekmezci - University of California, San FranciscoStephen Bagley - University of PennsylvaniaJacob S Young - University of California, San FranciscoRimas V Lukas - Northwestern UniversityAngela C Hirbe - Washington University in St. LouisBenjamin M Ellingson - University of California, Los AngelesJavier Villanueva-Meyer - University of California, San FranciscoAnna Lasorella - University of MiamiJann N Sarkaria - Mayo Clinic in ArizonaDavid H Gutmann - Washington University in St. LouisDaphne Haas-Kogan - Washington University in St. LouisEvanthia Galanis - Mayo Clinic in ArizonaSusan M Chang - University of California, San Francisco
- Neuro-oncology (Charlottesville, Va.), Vol.28(1)
- OXFORD UNIV PRESS INC; CARY
- 12
- The Dowskin Family Foundation, and by National Institutes of Health: 2UM1-CA186644-06, 1R37CA262510-01A1, 1R21CA282543 The Sylvester Comprehensive Cancer Center: 5P30CA240139-04
There was no manuscript-targeted external funding. Outside of the submitted work, M.I.D. was supported in part by The Sylvester Comprehensive Cancer Center Support Grant 5P30CA240139-04, The Dowskin Family Foundation, and by National Institutes of Health (NIH) grants 2UM1-CA186644-06, 1R37CA262510-01A1, and 1R21CA282543.
- Miller School of Medicine; UMMG Department of Neurology; UMMG Dept of Neurology - Neuro-Oncology Div; Biochemistry & Molecular Biology Research; UMMG Dept of Pediatrics - Hematology/Oncology/Stem Cell Transp; UMMG Department of Pediatrics
- English
- Journal article
- 41191923
- 991032856119802976